Original Article
Journal of Human Hypertension (2005) 19, 373–379. doi:10.1038/sj.jhh.1001834 Published online 10 February 2005
Cancer pattern among hypertensive patients in North Karelia, Finland
This work has not been published elsewhere in whole or in part. There are no potential conflicts of interest. The research was funded with a grant from the Finnish Cultural Foundation.
A M Lindgren1, A M Nissinen1,2,3, J O Tuomilehto2,4,5 and E Pukkala6
- 1Department of Public Health and General Practice, University of Kuopio, Finland
- 2Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland
- 3Department of Neurology, Kuopio University Hospital, Finland
- 4Department of Public Health, University of Helsinki, Helsinki, Finland
- 5South Ostrobotnia Central Hospital, Seinäjoki, Finland
- 6Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
Correspondence: Dr A Lindgren, Department of Public Health and General Practice, University of Kuopio, PB 1627, 70211 Kuopio, Finland. E-mail: Lindgren@hytti.uku.fi
Received 2 September 2004; Revised 16 December 2004; Accepted 17 December 2004; Published online 10 February 2005.
Abstract
The objective of this study was to determine the site-specific cancer incidence of hypertensive patients and examine the effect of blood pressure-related variables on the risk of cancers with elevated incidence among the hypertensive patients. A record linkage study of Hypertension Register of the North Karelia Project and the Finnish Cancer Registry was conducted. The mean follow-up time was 16 years. A total of 20 529 hypertensive patients were studied. Main outcome measures were standardised incidence ratios and hazard ratios. The overall cancer incidence was close to that of the general population for both men and women. The incidence rate for the kidney cancer was significantly increased in hypertensive patients (standardised incidence ratio 1.34, 95% confidence interval (CI) 1.11–1.60), as well as incidence rates for cancers of pancreas (1.26, 1.02–1.54), and endometrium (1.22, 1.01–1.44) in hypertensive women. The incidence of lung cancer was significantly decreased (0.86, 0.77–0.95). The incidence of liver cancer was elevated with borderline significance (1.36, 0.99–1.82). In Cox regression models, the use of antihypertensive drugs at baseline was a significant predictor of kidney (hazard ratio for use of antihypertensive drugs 1.89, 95% CI 0.96–3.75) and pancreatic cancer (1.78, 0.99–3.22) in women but not in men. The incidence of endometrial cancer or liver cancer was not related to blood pressure levels or the use of antihypertensive drugs. In women, obesity was a significant predictor of cancers of the endometrium, kidney and liver. In conclusion, increased occurrence of some cancer types among hypertensive patients seem to be partly explained by obesity and the use of antihypertensive drugs.
Keywords:
blood pressure, antihypertensive drugs, kidney cancer, endometrial cancer, pancreatic cancer, liver cancer
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Journal of Cerebral Blood Flow & Metabolism Original Article
Hypertension, diuretics and breast cancer risk
Journal of Human Hypertension Original Article
Hypertension, diuretics and breast cancer risk
Journal of Human Hypertension Original Article
Blood pressure and renal cancer risk: the HUNT Study in Norway
British Journal of Cancer Scientific Correspondence
